IRIS
STAGNO, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 60
EU - Europa 23
NA - Nord America 9
Totale 92
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 49
IT - Italia 12
US - Stati Uniti d'America 8
CN - Cina 6
AT - Austria 3
FI - Finlandia 3
FR - Francia 2
ID - Indonesia 2
DK - Danimarca 1
IL - Israele 1
IN - India 1
JM - Giamaica 1
KZ - Kazakistan 1
RU - Federazione Russa 1
SE - Svezia 1
Totale 92
Salva come PNG Salva come JPEG
Città #
Singapore 43
Messina 4
Trapani 4
Vienna 3
Guangzhou 2
Helsinki 2
Jakarta 2
Palermo 2
Xiamen 2
Almaty 1
Espoo 1
Mumbai 1
Scandicci 1
Stockholm 1
Tel Aviv 1
Totale 70
Salva come PNG Salva come JPEG
Nome #
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 19
Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw 14
Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors 14
Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management 9
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey 7
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 6
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients 5
Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms 4
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 4
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2‑OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 4
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 4
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection 4
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 4
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 4
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study 4
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 3
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 2
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 2
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 2
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 2
On the road to treatment-free remission in chronic myeloid leukemia: what about ‘the others’? 2
Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia 2
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 2
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 2
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 2
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia 2
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study 2
Totale 131
Salva come PNG Salva come JPEG
Categoria #
all - tutte 772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202429 0 0 0 0 0 0 0 0 0 11 2 16
2024/2025102 20 0 0 24 54 4 0 0 0 0 0 0
Totale 131